Based on these findings we believe that parallel targeting of beta cell function and mass is necessary to successfully treat diabetes. (dresden-ipp.de)
In type 1 diabetes, beta cells are destroyed while type 2 diabetes is associated with impaired beta cell function and insulin resistance. (scicasts.com)
ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead product candidate VC - 01 in patients with type 1 diabetes who have minimal to no insulin - producing beta cell function. (viacyte.com)